Skip to main content

Advertisement

SpringerLink
Log in

Predictors for symptom improvement in overactive bladder patients treated with imidafenacin

  • Original Article
  • Published:
Journal of Inclusion Phenomena and Macrocyclic Chemistry Aims and scope Submit manuscript

Abstract

The objective of this investigation is to ascertain the determinants associated with the amelioration of symptoms in female patients suffering from overactive bladder (OAB) following treatment with 0.2 mg of imidafenacin. The study included 66 female OAB patients who had been prescribed a daily dose of 0.2 mg imidafenacin for a minimum of 3 months, spanning from March 2018 to June 2020. Various clinical parameters including age, coexistence of additional voiding symptoms, prior history of urological surgeries, and responses to the Overactive Bladder Symptom Score questionnaire (OABSS), both pre- and post-initiation of imidafenacin therapy, were evaluated. The mean total OABSS scores recorded before and 3 months subsequent to imidafenacin therapy were 8.36 ± 3.65 and 5.15 ± 3.22, respectively. Following the 3-month course of imidafenacin treatment, there was a statistically significant improvement in both the total OABSS score and the severity of OAB symptoms (p < 0.001 for both). Prior to treatment initiation, Group B (n = 38) exhibited significantly higher total OABSS scores and subscores compared to Group A (n = 28) (p < 0.05). Multivariable analysis identified the OABSS subscores for items 1 and 3 prior to treatment as significant predictors for the improvement of OAB severity subsequent to imidafenacin therapy (p = 0.046, OR 3.10, 95% CI 1.019–9.440 and p < 0.001, OR 2.77, 95% CI 1.671–4.587, respectively). Consequently, imidafenacin emerges as an efficacious therapeutic agent for alleviating OAB severity in female patients, with the OABSS subscores for items 1 and 3 prior to treatment initiation holding potential utility in predicting the efficacy of imidafenacin in managing OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Drake, M.J.: Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol. Urodyn. 33, 622–624 (2014)

    Article  PubMed  Google Scholar 

  2. Milsom, I., Kaplan, S.A., Coyne, K.S., Sexton, C.C., Kopp, Z.S.: Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80, 90–96 (2012)

    Article  PubMed  Google Scholar 

  3. Abrams, P., Kelleher, C.J., Kerr, L.A., Rogers, R.G.: Overactive bladder significantly affects quality of life. Am. J. Manag. Care 6, S580–S590 (2000)

    CAS  PubMed  Google Scholar 

  4. Kobelt, G., Kirchberger, I., Malone-Lee, J.: Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 83, 583–590 (1999)

    Article  CAS  PubMed  Google Scholar 

  5. Stewart, W.F., Van Rooyen, J.B., Cundiff, G.W., Abrams, P., Herzog, A.R., Corey, R., Hunt, T.L., Wein, A.J.: Prevalence and burden of overactive bladder in the United States. World J. Urol. 20, 327–336 (2003)

    Article  CAS  PubMed  Google Scholar 

  6. Liberman, J.N., Hunt, T.L., Stewart, W.F., Wein, A., Zhou, Z., Herzog, A.R., Lipton, R.B., Diokno, A.C.: Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 57, 1044–1050 (2001)

    Article  CAS  PubMed  Google Scholar 

  7. Getsios, D., El-Hadi, W., Caro, I., Caro, J.: Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations. Pharmacoeconomics 23, 995–1006 (2005)

    Article  CAS  PubMed  Google Scholar 

  8. Burgio, K.L.: Current perspectives on management of urgency using bladder and behavioral training. J. Am. Acad. Nurse Pract. 16, 4–7 (2004)

    PubMed  Google Scholar 

  9. Marinkovic, S.P., Rovner, E.S., Moldwin, R.M., Stanton, S.L., Gillen, L.M., Marinkovic, C.M.: The management of overactive bladder syndrome. BMJ 344, e2365 (2012)

    Article  PubMed  Google Scholar 

  10. Andersson, K.-E., Chapple, C.R., Cardozo, L., Cruz, F., Hashim, H., Michel, M.C., Tannenbaum, C., Wein, A.J.: Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr. Opin. Urol. 19, 380–394 (2009)

    Article  PubMed  Google Scholar 

  11. Chapple, C.R.: Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55, 33–46 (2000)

    Article  CAS  PubMed  Google Scholar 

  12. Kelleher, C.J., Cardozo, L.D., Khullar, V., Salvatore, S.: A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. 104, 988–993 (1997)

    Article  CAS  PubMed  Google Scholar 

  13. Giglio, D., Tobin, G.: Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 83, 259–269 (2009)

    Article  CAS  PubMed  Google Scholar 

  14. Kobayashi, F., Yageta, Y., Segawa, M., Matsuzawa, S.: Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. Arzneimittelforschung 57, 92–100 (2007)

    CAS  PubMed  Google Scholar 

  15. Homma, Y., Yoshida, M., Seki, N., Yokoyama, O., Kakizaki, H., Gotoh, M., Yamanishi, T., Yamaguchi, O., Takeda, M., Nishizawa, O.: Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68, 318–323 (2006)

    Article  PubMed  Google Scholar 

  16. Sexton, C.C., Notte, S.M., Maroulis, C., Dmochowski, R.R., Cardozo, L., Subramanian, D., Coyne, K.S.: Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int. J. Clin. Pract. 65, 567–585 (2011)

    Article  CAS  PubMed  Google Scholar 

  17. Madhuvrata, P., Cody, J.D., Ellis, G., Herbison, G.P., Hay-Smith, E.J.: Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 1, Cd005429 (2012)

    PubMed  Google Scholar 

  18. Murakami, S., Yoshida, M., Iwashita, H., Otani, M., Miyamae, K., Masunaga, K., Miyamoto, Y., Inadome, A., Ueda, S.: Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol. Int. 71, 290–298 (2003)

    Article  CAS  PubMed  Google Scholar 

  19. Park, C., Park, J., Choo, M.-S., Kim, J.C., Lee, J.G., Lee, J.Z., Lee, K.-S., Kim, D.Y., Lee, S.-J., Seo, J.T.: A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder. Int. J. Clin. Pract. 68, 188–196 (2014)

    Article  CAS  PubMed  Google Scholar 

  20. Homma, Y., Yamaguchi, O.: A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int. J. Urol. 16, 499–506 (2009)

    Article  CAS  PubMed  Google Scholar 

  21. Hsiao, S.-M., Liao, C.-H., Lin, H.-H., Kuo, H.-C.: Duration of antimuscarinic administration for treatment of overactive bladder before which one can assess efficacy: an analysis of predictive factors. Int. Neurourol. J. 19, 171–177 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  22. Khullar, V., Hill, S., Laval, K.-U., Schiøtz, H.A., Jonas, U., Versi, E.: Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 64, 269–274 (2004)

    Article  PubMed  Google Scholar 

  23. Guzman-Negron, J., Vasavada, S.: Management of overactive bladder in the face of high grade prolapse. Curr. Urol. Rep. 18, 12 (2017)

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Wooseop Seong and Dong Gil Shin contributed equally to this work as co-first authors. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. RS-2023-00277502).

Author information

Authors and Affiliations

  1. Department of Urology, Pusan National University Hospital, 179 Gudeok-Ro, Seo-Gu, Busan, 49241, South Korea

    Wooseop Seong, Dong Gil Shin, Seunghyeon Kim, Tae Nam Kim, Jeong Zoo Lee, Kyoungha Jang & Hyeon Woo Kim

  2. Department of Urology, Pusan National University School of Medicine, 179 Gudeok-Ro, Seo-Gu, Busan, 49241, South Korea

    Dong Gil Shin, Tae Nam Kim, Jeong Zoo Lee & Hyeon Woo Kim

  3. Department of Mechatronics Engineering, Chonnam National University, 50 Daehak-Ro, Yeosu, Jeonnam, 59626, South Korea

    Yangkyu Park

Authors
  1. Wooseop Seong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Gil Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seunghyeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tae Nam Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeong Zoo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yangkyu Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kyoungha Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hyeon Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Wooseop Seong and Dong GIl Shin wrote the main manuscript text. Kyoungha Jang, Seunghyeon Kim prepared figures 1 and 2. Tae Nam Kim and Jeong Zoo Lee prepared tables 1, 2 and 3. Yangkyu Park has conducted statistical analysis. Hyeon Woo Kim has supervised the whole manuscript process. All authors reviewed the manuscript.

Corresponding author

Correspondence to Hyeon Woo Kim.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seong, W., Shin, D.G., Kim, S. et al. Predictors for symptom improvement in overactive bladder patients treated with imidafenacin. J Incl Phenom Macrocycl Chem (2024). https://doi.org/10.1007/s10847-024-01237-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10847-024-01237-1

Keywords

Search

Navigation